Proteome-wide cellular immunity approach to P. falciparum antigen identification

用于恶性疟原虫抗原鉴定的蛋白质组细胞免疫方法

• 批准号: 8131138
• 负责人: Denise L. Doolan
• 金额: $ 59.79万
• 依托单位: QUEENSLAND INSTITUTE OF MEDICAL RESEARCH
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-08-15 至 2013-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8131138
• 关键词: Adenoviruses; Affinity; Algorithms; Alleles; Amino Acid Sequence; Antigen Targeting; Antigens; Binding; Bioinformatics; Biological Assay; Blast Cell; CD4 Positive T Lymphocytes; CD8B1 gene; Cellular Assay; Cellular Immunity; Data; Data Set; Databases; Elements; Epitopes; Erythrocytes; Ethnic Origin; Exposure to; Gene Expression Profile; Genes; Genetic; Genome; Genomics; HLA-A1 Antigen; HLA-A3 Antigen; HLA-DR Antigens; Human; Immune; Immune response; Immunity; Immunodominant Antigens; Immunodominant Epitopes; In Vitro; Individual; Infection; Interferons; Life Cycle Stages; MHC Class I Genes; MHC binding peptide; Malaria Vaccines; Mining; Mus; Open Reading Frames; Orthologous Gene; Outcome; Parasites; Peptides; Peripheral Blood Mononuclear Cell; Plasmodium; Plasmodium falciparum; Population; Poxviridae; Proteins; Proteome; Proteomics; Recombinants; Regimen; Research; Scanning; Screening procedure; Solutions; Sporozoites; Staging; Sterility; Subunit Vaccines; T-Lymphocyte Epitopes; Testing; Vaccines; Variant; base; cross reactivity; design; efficacy evaluation; novel; novel strategies; transcriptomics; vaccine development

DESCRIPTION (provided by applicant): The long-term objective of this project is to identify and prioritize for malaria vaccine development novel P. falciparum antigens and epitopes that are recognized by individuals exposed to P. falciparum in the context of multiple genetic restrictions, by mining the P. falciparum genomic sequence. The feasibility of a malaria vaccine is supported by experimental data demonstrating that protective immunity can be induced by exposure to intact Plasmodium parasites. The antigenic targets of this protection have not been identified. P. falciparum expresses an estimated 5,300 proteins, each of which is a potential target of protective immune responses. Although the P. falciparum genome, proteome, and transcriptome have now been elucidated, it has not been obvious how to use this information for vaccine development. The current application offers a solution to this problem, by applying an integrated approach that incorporates bioinformatic predictions, HLA supertype considerations, high-throughput MHC peptide binding assays, and cellular assays. The specific aims are to: (1) identify, from the complete set of approximately 2500 genes expressed in the pre-erythrocytic stage of the P. falciparum parasite life cycle, those proteins that correspond to immunodominant antigens recognized in the context of multiple genetic restrictions by individuals exposed to P. falciparum; (2) for a subset of the100 most immunodominant antigens, identify the CD8+ and CD4+ T epitopes that are the targets of P. falciparum parasite-induced immunity, and their associated HLA Class I and II restriction elements; (3) for 50 antigens, characterize five epitopes/antigen for extent of sequence conservation or immunological cross-reactivity between different Plasmodium strains; and (4) for 10 antigens, evaluate the capacity to protect against Plasmodium sporozoite challenge in mice. It is expected that the proposed research will result in the identification of novel P. falciparum antigens that will represent good candidates for a vaccine that would be effective in all ethnicities. Additionally, data will demonstrate whether protective immune responses are targeted against only a few immunodominant antigens, or are broadly distributed against a large range of antigens, and will therefore provide valuable information regarding the potential multivalency of candidate malaria vaccines. It is expected that the proposed research will have important outcomes for malaria vaccine development. It will identify novel P. falciparum antigens that should represent good candidates for a subunit malaria vaccine that would be effective in all human populations regardless of ethnicity. Additionally, data will demonstrate whether protective immune responses are targeted against only a few immunodominant antigens, or are broadly distributed against a large range of antigens, and will therefore provide valuable information regarding the potential multivalency of candidate malaria vaccines.

描述（由申请人提供）：该项目的长期目标是通过挖掘恶性疟原虫基因组序列，鉴定并优先考虑疟疾疫苗开发新型恶性疟原虫抗原和表位，这些抗原和表位在多种遗传限制的背景下被暴露于恶性疟原虫的个体识别。疟疾疫苗的可行性得到了实验数据的支持，这些数据表明，接触完整的疟原虫寄生虫可以诱导保护性免疫。这种保护的抗原靶点尚未确定。恶性疟原虫表达约5,300种蛋白质，每种蛋白质都是保护性免疫反应的潜在靶点。虽然恶性疟原虫基因组、蛋白质组和转录组现已阐明，但如何将这些信息用于疫苗开发尚不清楚。本申请通过应用结合生物信息学预测、HLA超型考虑、高通量MHC肽结合测定和细胞测定的综合方法来提供对该问题的解决方案。具体目标是：（1）从在恶性疟原虫生命周期的红细胞前期阶段中表达的约2500个基因的完整集合中鉴定对应于在暴露于恶性疟原虫的个体的多种遗传限制的背景下识别的免疫显性抗原的那些蛋白质;（2）对于100种最具免疫优势的抗原的一个子集，鉴定作为恶性疟原虫诱导免疫的靶点的CD 8+和CD 4 + T表位，以及它们相关的HLA I类和II类限制性元件;（3）对于50种抗原，表征5个表位/抗原的序列保守程度或不同疟原虫株之间的免疫交叉反应性;和（4）对于10种抗原，评价在小鼠中保护免受疟原虫子孢子攻击的能力。预计拟议的研究将导致新的恶性疟原虫抗原的鉴定，这将代表疫苗的良好候选者，这将是有效的所有种族。此外，数据将证明保护性免疫应答是否仅针对少数免疫显性抗原，或广泛分布针对大范围抗原，因此将提供关于候选疟疾疫苗的潜在多价性的有价值信息。预计拟议的研究将对疟疾疫苗的开发产生重要成果。它将确定新的恶性疟原虫抗原，这些抗原应该代表亚单位疟疾疫苗的良好候选者，该疫苗将在所有人群中有效，无论种族如何。此外，数据将证明保护性免疫应答是否仅针对少数免疫显性抗原，或广泛分布针对大范围抗原，因此将提供关于候选疟疾疫苗的潜在多价性的有价值信息。